Microorganism-Derived and Lipid-Based Smart Biochemical Cancer Drugs: A Smarter Biochemical Approach to Cancer Treatment

Devjit Datta

Microorganism-Derived and Lipid-Based Smart Biochemical Cancer Drugs: A Smarter Biochemical Approach to Cancer Treatment

Author(s)	Mr. Devjit Datta
Country	India
Abstract	The development of effective cancer therapeutics remains constrained by tumour heterogeneity, acquired drug resistance, dose-limiting toxicity, and the variable distribution of therapeutic compounds within malignant tissues. Microorganisms constitute a valuable source of pharmacologically active natural products, several of which have contributed to established anticancer therapies. Independently, lipid-based drug-delivery systems have demonstrated clinical utility and continue to be investigated for improving the delivery of small molecules, nucleic acids, and other therapeutic agents. However, combining microbial-derived anticancer compounds with rationally engineered lipid carriers requires compound-specific evaluation of pharmacological activity, formulation compatibility, and biological selectivity. This critical review examines the biochemical mechanisms of microorganism-derived anticancer agents and the potential contribution of liposomes, lipid nanoparticles, and stimulus-responsive lipid formulations to cancer drug delivery. It introduces the proposed Microbial–Lipid Biochemical Selectivity Framework (MLBSF), a conceptual approach for evaluating candidate molecules across five dimensions: compound identity and potency, carrier compatibility, tumour-directed delivery, biochemical target engagement, and therapeutic selectivity. The framework also identifies experimental endpoints and translational barriers relevant to candidate prioritisation. Particular attention is given to the distinction between established clinical evidence, preclinical observations, and hypotheses requiring experimental validation. The proposed framework does not assume that encapsulation necessarily improves therapeutic outcomes; instead, it establishes a comparative basis for testing whether a lipid formulation provides a measurable advantage over its unencapsulated counterpart. Integrating microbial natural-product discovery with rational lipid formulation may offer a useful direction for cancer drug development, provided that subsequent research demonstrates reproducibility, acceptable safety, and clinically meaningful benefit.
Keywords	Microbial natural products; anticancer agents; lipid nanoparticles; liposomes; cancer biochemistry; stimulus-responsive drug delivery; apoptosis; therapeutic selectivity; precision oncology; drug development.
Field	Medical / Pharmacy
Published In	Volume 8, Issue 5, September-October 2026
Published On	2026-10-12

View / Download PDF File

About IJFMR Fees & Payment Current Issue Publication Archive	Submit Research Paper Track Submission Status Publication Guidelines Publication Ethics Peer Review & Plagiarism	Join as a Reviewer Editors & Reviewers Reviewer Referral Program Get Reviewer Membership Certi.	Website/Journal Policies Usage Policy Content Policies Privacy Policy

Contact Us		+91-9687-828-838	editor@ijfmr.com

International Journal For Multidisciplinary Research

A Widely Indexed Open Access Peer Reviewed Multidisciplinary Bi-monthly Scholarly International Journal

Microorganism-Derived and Lipid-Based Smart Biochemical Cancer Drugs: A Smarter Biochemical Approach to Cancer Treatment

Share this